Antihyperlipidemic drugs and their novel formulation approaches: A review
SG Bhokare, PB Jadhav, MN Madibone
Hyperlipidemia is an elevated condition of lipid levels in the body and is known to speed up a process of atherosclerosis that mayprovefatalinthedevelopment of various cardiovascular diseases. Increase in lipids like LDL i.e. low density lipoproteins, cholesterol and triglycerides are mainly responsible for hyperlipidemia. Present pharmacotherapy for hyperlipidemia includes statins, niacin, fibric acid derivatives and cholesterol absorption inhibitors. 90% of the pharmacotherapy of hyperlipidemia includes statins and these statins also suffer from limitations like, inadequate solubility, less absorption, less bioavailability and ineffectiveness in lowering of cholesterol levels only upto maximum 40% risk reduction. These drugs are to be given on daily basis which make it cumbersome for patients. Novel Drug Delivery System is an advanced drug delivery system with improved solubility, absorption, bioavailability, drug potency, control drug release to give a sustained therapeutic effect, and target oriented to a desired tissue as well as patient compliance is good. So it is the need of hour to formulate such kind of drug delivery systems which will combat the limitations of anti hyperlipidemic therapy. The present review emphasise on applications of novel drug delivery systems in pharmacotherapy of anti hyperlipidemic drugs.